Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We determined the prevalence of allelic loss at 9p21 and mutations in CDKN2 in esophageal adenocarcinomas and investigated the order in which they occurred relative to the development of aneuploidy and cancer during neoplastic progression.
|
8934532 |
1996 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, frequently homozygous deletions occur in several kinds of cancer associated with the loss of tumour suppressor genes as p16 and p15.
|
16081515 |
2006 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clinical and histologic characteristics of 182 patients with 429 CMM from families with a founder mutation in CDKN2A (p16-Leiden mutation) were compared with 7512 patients with 7842 CMM from a population-based cancer registry.
|
21570156 |
2011 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The genes at the INK4A/ARF locus at 9p21 are frequently involved in human cancer.
|
11154239 |
2001 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The INK4 proteins are commonly lost or inactivated by mutations in diverse types of cancer, and they represent established or candidate tumor suppressors.
|
17654117 |
2007 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A significant increase in the frequency of CDKN2A methylation was identified during EC carcinogenesis: cancer vs. controls, odds ratio (OR) = 12.60 (95 % CI, 8.90-17.85); cancer vs. precancerous lesions, OR = 2.89 (95% CI, 2.20-3.79); and precancerous lesions vs. controls, OR = 7.38, 95% (CI, 4.31-12.66).
|
28637022 |
2017 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Two different polymorphisms at positions 540 and 580 at the 3'UTR of exon 3 of p16 gene are implicated in several types of cancer, while their role in cervical cancer development remains rather vague.
|
29168898 |
2018 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We detected a deletion at the CDKN2A locus as being the most frequent genetic alteration in all cancer types.
|
24664538 |
2014 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The importance of the CDK4 locus in human cancer first became evident following the identification of a germ line CDK4-Arg24Cys (R24C) mutation, which abolishes the ability of CDK4 to bind to p16(INK4a).
|
11756559 |
2002 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
|
20340136 |
2010 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study examined whether participants who learned research results related to a germline CDKN2A variant known to be associated with increased risk of pancreatic cancer and malignant melanoma would pursue confirmatory testing and cancer screening, share the genetic information with health care providers and family, and change risk perceptions.
|
30992552 |
2019 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results are consistent with the idea that p16 allelic variants that decrease Cdk interaction predispose individuals who carry them to an increased risk of cancer.
|
7566978 |
1995 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the present study, we performed a meta-analysis to clarify whether there is an association of CDKN2A polymorphisms and cancer risk.
|
28466822 |
2017 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although very few mutations of p14ARF have been detected in some cancer types, changes in expression seem to play an important role in the development of other human cancers such as mesotheliomas.
|
11876522 |
2002 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Homozygous deletion of P16/CDKN2A is found in approximately 75% of mesotheliomas amd may be the most common genetic alteration in this cancer.
|
15950811 |
2005 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the lncRNA antisense non-coding RNA (ncRNA) in the INK4 locus (ANRIL), the rs1333048 A/C, rs4977574 A/G, and rs10757278 A/G polymorphisms, but not rs1333045 C/T, were correlated with overall cancer risk.
|
29802154 |
2018 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further, the germline p16 mutation segregated with cancer predisposition within the family.
|
12352668 |
2002 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The obtained results allow us to conclude: (i) survival times of 500 C/G carriers vs. cumulating proportion surviving was not statistically significant; (ii) CDKN2a polymorphism 500 C/G correlated with Ala148Thr; (iii) no correlation was observed between the 500 C/G polymorphism and age of diagnosis, localization of primary melanoma and survival time; (iv) we did not find correlation between 500 C/G and type of cancer in the family; (v) changes in the CDKN2a gene were not found in patients with second cancer.
|
17351674 |
2007 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We measured p16 (CDKN2A/INK4A) lesions (loss of heterozygosity, mutations, and CpG island methylation), p53 (TP53) lesions (loss of heterozygosity, mutation) and ploidy abnormalities (aneuploidy, tetraploidy) within each Barrett's esophagus segment of a cohort of 267 research participants, who were followed prospectively with cancer as an outcome.
|
15492292 |
2004 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We examined the risk of non-melanoma cancer in 117 mutation-positive and 136 mutation-negative members from 15 families that had at least two first degree relatives with melanoma and CDKN2A mutations restricting the analysis to the period after the families were ascertained (that is, the prospective period) and using individual mutation data.
|
15173226 |
2004 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Homozygous deletion of p16 (CDKN2A) by fluorescence in situ hybridization (FISH) has been shown to be a good marker of malignancy in mesothelial proliferations, but correlations of p16 status between atypical surface proliferations and underlying mesothelioma have not been described.
|
24503757 |
2014 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.
|
18981015 |
2008 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We studied oral mucosa biopsies with epithelial dysplasia from 78 patients enrolled in a published 4-years' followup cohort, in which cancer risk for patients with p16 methylation-positive dysplasia was significantly higher than those without p16 methylation (by 150-bp MSP and bisulfite sequencing; +133 ~ +283, transcription starting site, +1).
|
21569495 |
2011 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
After further stratification of the cancer group into different clinical-pathologic parameters, there were significant associations in the sex and LN involvement groups in MK gene; alcohol consumption group in p16 gene; age and cell differentiation groups in p21 gene; age and tumour location groups in p53 gene; but we fail to find any significant association with IL-4 gene polymorphisms.
|
16289646 |
2005 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The CDKN2A (p16) gene and human cancer.
|
9132280 |
1997 |